{"id":3079,"date":"2025-03-05T16:45:40","date_gmt":"2025-03-05T13:45:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3079"},"modified":"2025-03-07T12:54:07","modified_gmt":"2025-03-07T09:54:07","slug":"pepgen-temporarily-pauses-exon-51-skipping-study","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/pepgen-temporarily-pauses-exon-51-skipping-study\/","title":{"rendered":"PepGen, Ekzon 51 Atlama \u00c7al\u0131\u015fmas\u0131n\u0131 Ge\u00e7ici Olarak Durdurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">\u015eiddetli n\u00f6rom\u00fcsk\u00fcler ve n\u00f6rolojik hastal\u0131klar\u0131n tedavisini d\u00f6n\u00fc\u015ft\u00fcrmeyi hedefleyen yeni nesil oligon\u00fckleotid tedavilerini geli\u015ftiren klinik a\u015famadaki biyoteknoloji \u015firketi PepGen, bug\u00fcn Duchenne kas distrofisi (DMD) hastalar\u0131nda PGN-EDO51&#039;in Faz 2 CONNECT2-EDO51 \u00e7al\u0131\u015fmas\u0131n\u0131, \u015eirket devam eden Faz 2 CONNECT1-EDO51 \u00e7al\u0131\u015fmas\u0131ndaki 10 mg\/kg kohortundan elde edilen sonu\u00e7lar\u0131 inceleyene kadar ge\u00e7ici olarak durdurma karar\u0131n\u0131 g\u00f6n\u00fcll\u00fc olarak ald\u0131\u011f\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CONNECT1 \u00e7al\u0131\u015fmas\u0131n\u0131n ilk iki kohortu tamamen kay\u0131tl\u0131d\u0131r ve 10 mg\/kg kohortundan elde edilen verilerin 2025&#039;in \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011finde a\u00e7\u0131klanmas\u0131 beklenmektedir. \u015eirketin 23 Ocak 2025 tarihli son g\u00fcvenlik g\u00fcncellemesinden bu yana PGN-EDO51 ile ilgili yeni bir g\u00fcvenlik sorunu g\u00f6zlemlenmemi\u015ftir.<\/p>","protected":false},"excerpt":{"rendered":"<p>PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[137,275,122,193,194,77,273,274],"class_list":["post-3079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trial","tag-connect1-edo51","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-pepgen","tag-pgn-edo51"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3079"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}